Welcome to our dedicated page for Waldencast plc SEC filings (Ticker: WALD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Waldencast plc (NASDAQ: WALD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Waldencast files with the U.S. Securities and Exchange Commission primarily on Form 20-F for its annual report and Form 6-K for interim updates, transaction details, and other material information.
Recent Form 6-K filings referenced by the company include current reports furnishing quarterly and half-year financial results, such as operating results for specific quarters and six-month periods, along with trading updates. One Form 6-K includes Waldencast’s unaudited interim consolidated financial statements for the six months ended June 30, 2025 as an exhibit, while another furnishes a press release detailing Q2 2025 results and a Q3 2025 trading update.
Waldencast also uses Form 6-K to disclose material agreements and corporate actions. Examples include a credit agreement with lenders associated with the Lumina Capital Management group and agreements related to the sale and coexistence of the “Obagi” trademark in Japan with Rohto Pharmaceutical Co., Ltd. These documents, referenced as exhibits to Form 6-K, outline key terms of financing and trademark transactions that the company associates with its efforts to strengthen its balance sheet and refine its brand portfolio.
Through its SEC filings, Waldencast provides segment-level information for Obagi Medical and Milk Makeup, along with definitions and reconciliations for non-GAAP measures such as adjusted gross profit and adjusted EBITDA. Filings also describe the company’s ongoing strategic review of alternatives, its risk factors by reference to its Form 20-F, and the incorporation of certain 6-K reports into existing registration statements.
On Stock Titan, these filings can be viewed alongside AI-powered summaries that clarify the main points of each report, highlight segment performance, and point out notable items such as new credit facilities, trademark transactions, or updates on the strategic review. Users can follow new Form 6-K submissions in real time to monitor how Waldencast communicates financial results, capital structure changes, and other regulatory disclosures.
Waldencast plc reported the results of its annual general meeting held on January 14, 2026. Shareholders present in person or by proxy represented 92,255,519 ordinary shares, equal to 72.05% of the outstanding ordinary shares as of the December 9, 2025 record date.
Three Class III directors were re-appointed to serve until the general meeting to be held in 2028. Votes in favor were 91,182,921 for Michel Brousset, 89,332,770 for Felipe Dutra, and 79,174,145 for Simon Dai, with the remainder cast as against or abstain for each. Shareholders also ratified the selection of Deloitte & Touche LLP as independent registered public accounting firm until the conclusion of the next annual general meeting, with 89,968,656 votes for, 25,639 against, and 2,261,224 abstentions.
Waldencast plc is registering up to 9,819,000 Class A ordinary shares for resale by existing holders, not for a new capital raise. These shares are contingent consideration from the Novaestiq acquisition and relate to exclusive U.S. commercialization rights for saypha-branded cosmetic filler products. The package includes 3,273,000 shares already earned upon FDA approval of Obagi saypha MagIQ injectable hyaluronic acid gel and up to 6,546,000 additional shares tied to future sales milestones.
The sellers, primarily Croma-Pharma GmbH and NVQ Investors Holding, LLC, may sell their shares over time under this shelf prospectus, while Waldencast receives no proceeds from these resales but covers registration expenses. The Novaestiq deal also includes $3.0 million in cash and a 5.0% share of net sales of Phase 1 products above $120.0 million, plus lock-up schedules that stagger when milestone shares can be sold, which may influence future trading volumes in Waldencast stock.
Waldencast plc has furnished a Form 6-K announcing that it has released its Q2 2025 financial results and a Q3 2025 trading update. The company reports on business and financial performance for the three and six months ended June 30, 2025, and provides a trading update for the three months ended September 30, 2025, via a press release attached as Exhibit 99.1. The Form 6-K states that this information is being furnished rather than filed and will only be incorporated by reference into other filings if specifically referenced.
Waldencast plc filed a Form 6-K to provide its unaudited interim consolidated financial statements for the six months ended June 30, 2025. These H1 2025 interim financials are furnished as Exhibit 99.1.
The filing also lists several material agreements as exhibits, including a Credit Agreement dated November 14, 2025 involving Milk Makeup LLC, Obagi Cosmeceuticals LLC, Waldencast Partners plc as parent guarantor, various lenders and LSSF II Offshore Investments, LP as administrative agent. In addition, it includes a Trademark Transfer Agreement and a Trademark Coexistence Agreement, both dated November 13, 2025, between Rohto Pharmaceutical Co., Ltd. and Obagi Cosmeceuticals LLC.
The report and its exhibits are incorporated by reference into Waldencast’s existing registration statements on Form S-8 and Form F-3, meaning these interim financials and agreements now form part of those shelf and incentive plan disclosures.
Waldencast plc reported updates via a Form 6-K, noting the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. The company characterized these steps as strengthening its balance sheet.
A press release dated November 14, 2025 is attached as Exhibit 99.1 for further details. The information in this report, including the exhibit, is designated as not “filed” under Section 18 of the Exchange Act.